MetMark is advancing early diabetes risk tests by measuring alpha-hydroxybutyrate (AHB), a metabolic biomarker associated with insulin resistance, dysglycemia and future type 2 diabetes risk. Research suggests elevated AHB may reveal metabolic changes even when conventional fasting glucose and HbA1c measurements remain within normal ranges. MetMark uses DirectSens’ XpressGT enzymatic assay, allowing AHB to be measured in serum or plasma using standard high-throughput clinical chemistry analyzers rather than specialized mass spectrometry.
For Precision Diabetes, making AHB testing compatible with routine laboratory infrastructure could broaden access to earlier metabolic risk assessment. The company holds exclusive U.S. commercialization rights for specified diabetes and prediabetes laboratory-developed test applications and will oversee sales, implementation and reimbursement. The partnership also gives DirectSens a pathway into the U.S. diagnostics market while providing laboratories with a potentially scalable addition to existing diabetes testing workflows.
Image Credit: Precision Diabetes
Key Themes Behind This Trend
- Early Biomarker Screening
- Metabolic biomarkers such as AHB create openings for diagnostics that detect diabetes risk before conventional glucose measures show abnormalities.
- Routine Lab Integration
- Compatibility with existing high-throughput clinical chemistry analyzers expands the potential for advanced testing to scale without specialized equipment.
- Predictive Metabolic Health
- Earlier visibility into insulin resistance and dysglycemia supports new preventive care models built around risk prediction rather than disease confirmation.
Where This Applies
- Clinical Diagnostics
- Laboratories gain opportunities to expand diabetes testing menus with biomarker-based assays that fit established serum and plasma workflows.
- Preventive Healthcare
- Health systems can use earlier metabolic risk signals to support more personalized intervention strategies before type 2 diabetes develops.
- Biotechnology
- Assay developers benefit from pathways that translate specialized biomarker science into commercially scalable diagnostic platforms.
